Results 101 to 110 of about 27,235 (300)

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

iScience
Summary: A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely effective bebtelovimab, are
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, Yuko Okemoto-Nakamura, Yoshimi Shimizu, Motohiko Ogawa, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Mika K. Kaneko, Masayoshi Fukasawa, Yukinari Kato, Kohji Noguchi   +12 more
doaj  

Construction of a diabody (small recombinant bispecific antibody) using a refolding system [PDF]

, 2000
Shin-ichi Takemura, Ryutaro Asano, Kouhei Tsumoto, Shinji Ebara, Naoki Sakurai, Yu Katayose, Hideaki Kodama, Hiroshi Yoshida, Masanori Suzuki, Kohzoh Imai, Seiki Matsuno, Toshio Kudo, Izumi Kumagai   +12 more
openalex   +1 more source

Patient‐derived xenograft models in pan‐cancer: From bench to clinic

Interdisciplinary Medicine, EarlyView.
Abstract Patient‐derived xenograft (PDX) models provide a robust preclinical platform that preserves the genetic and phenotypic heterogeneity of patient tumors while mirroring their tumor genetic characteristics, which retain malignant cells and the tumor pathological structure, making them valuable for studying tumor progression and developing ...
Jiatong Li, Ao Gu, Nannan Tang, Gokhan Zengin, Meng‐Yao Li, Yingbin Liu   +5 more
wiley   +1 more source

[Bispecific antibodies: what future?].

Medecine sciences : M/S, 2009
Monoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR-expressing cells. Attempts to improve the cytotoxicity of antibodies, particularly in the cancer field, have led to the design
Pèlegrin, André, Robert, Bruno
openaire   +2 more sources

CD3 directed bispecific antibodies induce increased lymphocyte–endothelial cell interactions in vitro [PDF]

, 2000
Grietje Molema, Jan Willem Cohen Tervaert, B. J. Kroesen, Wijnand Helfrich, Dirk Meijer, L. F. M. H. de Leij   +5 more
openalex   +1 more source

Advanced single‐cell RNA sequencing in tumor immunology

Interdisciplinary Medicine, EarlyView.
This review highlights the applications of advanced single‐cell RNA sequencing (scRNA‐seq) technologies in tumor immunology. It summarizes representative scRNA‐seq methods according to technical principles, with a focus on single‐cell T cell receptor sequencing. This review also discusses how scRNA‐seq is used to construct immune cell atlases of tumors,
Yilong Liu, Xiyuan Yu, Zhipeng Han, Qiuyang Wei, Qi Niu, Chaoyong Yang, Jie P. Li, Zijian Guo, Huimin Zhang   +8 more
wiley   +1 more source

Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3) [PDF]

, 2001
Rainer Riesenberg, Alexander Büchner, Heike Pohla, Horst Lindhofer   +3 more
openalex   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, EarlyView.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Large scale controlled Fab exchange GMP process to prepare bispecific antibodies

Frontiers in Bioengineering and Biotechnology
Objective: Bispecific antibodies (BsAbs) have demonstrated significant therapeutic impacts for the treatment of a broad spectrum of diseases that include oncology, auto-immune, and infectious diseases.
Xia Yao, Mingquan Xie, Yinyin Ben, Yixiang Zhu, Gaoqiang Yang, Simon Chi Wai Kwong, Zhengliang Zhang, Mark L. Chiu, Mark L. Chiu   +8 more
doaj   +1 more source

Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV [PDF]

, 2001
Hilke Brühl, Josef Cihak, M. Stangassinger, Detlef Schlöndorff, Matthias Mack   +4 more
openalex   +1 more source